0 results available. Select is focused ,type to refine list, press Down to open the menu,
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunolo...
The following section summarizes insights on Sanofi L's Debt / Common Equity:
We've identified the following companies as similar to Sanofi L because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
A ratio that measures the level of the debt relative to the book value of common equity.
Debt / Equity is defined as:
Total Debt
(/) Total Common Equity
(=) Debt / Equity
Debt / Equity for Sanofi is calculated as follows:
Total Debt [ 17.913 B]
(/) Total Common Equity [ 77.507 B ]
(=) Debt / Equity [ 23.1% ]
The tables below summarizes the trend in Sanofi’s Debt / Equity over the last five years:
| Fiscal Year | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2020-12-31 | 23.675 B | 63.106 B | 37.5% |
| 2021-12-31 | 22.415 B | 68.681 B | 32.6% |
| 2022-12-31 | 21.212 B | 74.784 B | 28.4% |
| 2023-12-31 | 18.423 B | 74.04 B | 24.9% |
| 2024-12-31 | 17.913 B | 77.507 B | 23.1% |
The tables below summarizes the trend in Sanofi’s Debt / Equity over the last four quarters:
| Fiscal Quarter | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2024-03-31 | 18.423 B | 74.04 B | 24.9% |
| 2024-06-30 | 23.751 B | 72.69 B | 32.7% |
| 2024-09-30 | 23.751 B | 72.69 B | 32.7% |
| 2024-12-31 | 17.913 B | 77.507 B | 23.1% |
The higher the ratio, the more debt the company has in its capital structure.
Read More on HBR: Debt / Equity Ratio